Shares of Odonate Therapeutics Inc (NASDAQ:ODT) have earned an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy recommendation.
Brokers have set a one year consensus price target of $45.00 for the company and are predicting that the company will post ($1.08) earnings per share for the current quarter, according to Zacks. Zacks has also given Odonate Therapeutics an industry rank of 58 out of 255 based on the ratings given to its competitors.
ODT has been the topic of a number of recent analyst reports. ValuEngine downgraded shares of Odonate Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. Zacks Investment Research downgraded shares of Odonate Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, November 12th.
NASDAQ:ODT traded up $1.70 on Wednesday, reaching $34.98. 124,251 shares of the company’s stock were exchanged, compared to its average volume of 92,523. The stock has a fifty day simple moving average of $32.50 and a 200-day simple moving average of $30.95. Odonate Therapeutics has a 52 week low of $11.54 and a 52 week high of $43.75. The firm has a market cap of $1.10 billion, a price-to-earnings ratio of -9.61 and a beta of 1.83.
Odonate Therapeutics (NASDAQ:ODT) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.88) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.19. On average, equities analysts predict that Odonate Therapeutics will post -4.23 EPS for the current fiscal year.
About Odonate Therapeutics
Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.
Further Reading: What sectors are represented in the FTSE 100 index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.